Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects the preoperative combination therapies
of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early
stage HER-2 positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eric Winer, MD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Massachusetts General Hospital Yale University